Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | CASP7 | P55210 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653482 | 0.93 | FOLH1 (0.41) | FOLH1SIRT5HTTPTGER4HDAC1 | |
| SCHEMBL5655056 | 0.84 | FOLH1 (0.51) | FOLH1SIRT5HTTPTGER4 | |
| SCHEMBL5655045 | 0.82 | PTGER4 (0.52) | FOLH1SIRT5HTTPTGER4HDAC1 | |
| SCHEMBL5655924 | 0.81 | HDAC1 (0.47) | FOLH1SIRT5PTGER4HDAC1HDAC4 | |
| SCHEMBL5654551 | 0.81 | HDAC1 (0.47) | FOLH1SIRT5PTGER4HDAC1 | |
| SCHEMBL5652247 | 0.81 | HDAC1 (0.49) | FOLH1SIRT5PTGER4HDAC1HDAC4 | |
| SCHEMBL5654619 | 0.80 | PTGER4 (0.48) | FOLH1SIRT5PTGER4HDAC1HDAC4 | |
| SCHEMBL5654868 | 0.80 | HDAC1 (0.46) | FOLH1SIRT5PTGER4HDAC1HDAC4 | |
| SCHEMBL5654879 | 0.79 | HDAC1 (0.49) | SIRT5PTGER4HDAC1HDAC4HDAC6 | |
| SCHEMBL5651770 | 0.79 | PTGER4 (0.51) | FOLH1SIRT5PTGER4HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | claimed |
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | FOLH1 2951/4885SIRT5 1504/4885HTT 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.